- Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for More Than 1 Year
-
Kim Y, Kim JS, Kang B, Kim I, Kim H, Lee WS, Sang YB, Jung S, An C, Kim C, Chon HJ
- KMID: 2560256
- Cancer Res Treat.
- 2024 Oct;56(4):1231-1239.
- doi: 10.4143/crt.2024.237
Purpose Since 2020, atezolizumab plus bevacizumab (Ate/Bev) has been the standard first-line therapy for unresectable hepatocellular carcinoma (HCC), but long-term treatment studies are limited. This study evaluated the clinical characteristics... -
- CITED
-
- Close
- SHARE
-
- Close
